|
|
Vaccine Detail
|
ALVAC-AI-H5 |
| Vaccine Information |
- Vaccine Name: ALVAC-AI-H5
- Target Pathogen: Influenza virus
- Target Disease: Influenza (flu)
- Vaccine Ontology ID: VO_0004747
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- Vector:
- Preparation: ALVAC vaccine expressing the haemagglutinin of a highly pathogenic (HP) H5N1 avian influenza virus (AIV) (A/chicken/Indonesia/7/03) in pig(Kyriakis et al., 2009).
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Pig Response
- Vaccination Protocol: Pigs were vaccinated twice, with a 4-week interval, with a canarypox (ALVAC) vector vaccine combined with an oil-in-water adjuvant, with the unadjuvanted NYVAC, or left unvaccinated (Kyriakis et al., 2009).
- Vaccine Immune Response Type: VO_0003057
- Challenge Protocol: Six weeks after the second vaccination, all pigs were challenged intra-tracheally with low pathogenic (LP) H5N2 AIV A/chicken/Belgium/150/99 (Kyriakis et al., 2009).
- Efficacy: The NYVAC and ALVAC adjuvanted vaccines consistently induced higher antibody titres than TROVAC or NYVAC without adjuvant. Following challenge, the H5N2 challenge virus was isolated from all unvaccinated pigs, while 19 out of 21 vaccinates showed complete virological protection (Kyriakis et al., 2009).
|
| References |
Kyriakis et al., 2009: Kyriakis CS, De Vleeschauwer A, Barbé F, Bublot M, Van Reeth K. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs. Vaccine. 2009; 27(16); 2258-2264. [PubMed: 19428840].
|
|
